Navigation Links
Phase 1 Trial of Whole-Parasite Malaria Vaccine to Begin
Date:4/22/2009

FDA approval for testing in humans watershed moment for unique malaria

vaccine approach

ROCKVILLE, Md., April 23 /PRNewswire/ -- In a move that highlights the strength of public-private collaboration in tackling international health challenges, the Maryland-based company Sanaria Inc., with support from the PATH Malaria Vaccine Initiative (MVI), has initiated a Phase 1 clinical trial -- the first tests in adult volunteers -- of its unique malaria vaccine candidate. Unlike other malaria vaccine candidates, Sanaria's approach deploys a weakened form of the whole malaria parasite harvested from irradiated mosquitoes instead of small portions of the parasite.

Having met the US Food and Drug Administration's (FDA) rigorous safety, sterility, purity, potency, and reproducibility requirements for testing in humans, Sanaria's vaccine candidate is to be assessed in healthy US volunteers at two sites in Maryland -- the US Naval Medical Research Center Clinical Trials Center in Bethesda and the Center for Vaccine Development at the University of Maryland School of Medicine in Baltimore. Recruitment has begun for the safety and efficacy study that will involve some 104 volunteers, with inoculation of the first groups expected to begin in mid-May.

"Initiation of this trial expands the spectrum of malaria vaccines in clinical development today," said Dr. Christian Loucq, Director of MVI. "This trial marks a major achievement in a collaborative development effort that aims to determine whether Sanaria's vaccine candidate is safe and effective."

While most malaria vaccines in clinical development consist of recombinant or genetically engineered proteins that represent small portions of the parasite, Sanaria's Plasmodium falciparum sporozoite vaccine candidate contains a weakened form of the entire malaria parasite. While unique to the malaria vaccine field
'/>"/>

SOURCE Sanaria Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
2. ImQuest BioSciences Receives Phase I SBIR Grant to Develop a Novel Hepatitis C Virus Therapeutic Agent
3. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
4. Circassias Allergy Therapy Begins Phase II Clinical Trial in Asthma Patients
5. Elusys Anthrax Anti-Toxin, Anthim(TM), Enters Second Phase I Clinical Study
6. Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial
7. VentiRx Pharmaceuticals Initiates Phase I Clinical Trial of VTX-1463, a Novel TLR8 Agonist for the Treatment of Allergic Rhinitis
8. Novagali Pharma Completed a New Phase II With Cyclokat(R) in Dry Eye
9. Pfizer and Medivation Initiate Phase 3 Trial of Dimebon Added to Donepezil in Patients with Alzheimers Disease
10. Osprey Pharmaceuticals U.S.A., Inc. Initiates Phase Ib Clinical Trial in IgA Nephropathy
11. Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 26, 2014 Lexicon ... announced the completion of previously announced concurrent financing ... After fees and estimated offering expenses, Lexicon anticipates ... transactions.  The transactions consisted of: , ... stock, pursuant to a registration statement that has ...
(Date:11/26/2014)... Investor-Edge has initiated coverage on the following equities: VIVUS ... HZNP ), Endocyte Inc. (NASDAQ: ECYT ... Theravance Inc. (NASDAQ: THRX ). Free research on ... . On Tuesday, November 25, 2014, the NASDAQ Composite ... edged 0.02% lower, to finish the day at 17,814.94, and ...
(Date:11/26/2014)... 2014 Zynerba Pharmaceuticals , Inc., a ... transdermal synthetic cannabinoid treatments, today announced that the company ... Conference 2014. The conference will be held December 2 ... New York . Zynerba,s Chairman and CEO, ... on Tuesday, December 2. To listen to ...
Breaking Medicine Technology:Lexicon Announces Completion Of $280 Million In Financing Transactions 2Lexicon Announces Completion Of $280 Million In Financing Transactions 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2
... 16, 2011 Get content from European Parliament ... The European Parliament is expected to pass ... medicines from entering the legal distribution chain in ... reached patients in the last years. The legislation ...
... SUNNYVALE, Calif., Feb. 16, 2011 ... today announced it will showcase its network scanning solutions ... hospitals and patients at the Annual HIMSS Conference & ... The adoption of network scanners has gained tremendous ...
Cached Medicine Technology:Fujitsu to Showcase New Document Imaging Technologies for Improved Information Sharing and Record Keeping at HIMSS 2011 2Fujitsu to Showcase New Document Imaging Technologies for Improved Information Sharing and Record Keeping at HIMSS 2011 3
(Date:11/28/2014)... (PRWEB) November 28, 2014 The ... techniques such as Dynamic Neuromuscular Stabilization, Extracorporeal Shock ... analysis. After moving to upgraded facilities in 2011, ... clinic. Now, owner Dr. Lev Kalika has launched ... injury prevention lab in the country. , The ...
(Date:11/28/2014)... The holiday season is fast approaching. As ... new collection of fashionable party dresses. What’s more, the company ... these brand new outfits; the special offer is valid until ... online supplier and it has received a lot of requests ... specially designed to flatter various body shapes; they are available ...
(Date:11/28/2014)... Brosix is always making changes to its infrastructure architecture ... efficient, effective, and secure experience. Most recently, the company ... ability to setup local servers for each country or ... around the globe. , 2. The ability to setup ... require millions of users in one network. , 3. ...
(Date:11/28/2014)... Orlando, FL (PRWEB) November 28, 2014 ... management solutions, announced its Release v5.1 which provides ... and enhanced workflow options. , “As we ... we continue to provide more functionality and improved ... states Robert Gambotz, CEO for Novatus. “With the ...
(Date:11/28/2014)... 2014 Dr. Diane Walder, one of ... treatment to her practice called Ultrashape that is designed to ... inches in just six weeks. Ultrashape has been praised by ... in results when compared to other types of external fat ... it,” said Dr. Walder. , According to Dr. Walder, ...
Breaking Medicine News(10 mins):Health News:New York Dynamic Neuromuscular Rehabilitation Opens Nation's Most Advanced Movement Performance and Injury Prevention Lab 2Health News:New York Dynamic Neuromuscular Rehabilitation Opens Nation's Most Advanced Movement Performance and Injury Prevention Lab 3Health News:Trendy Party Dresses For The Coming Holiday Season From Balfleet.com 2Health News:Brosix Infrastructure Architecture Changes to Benefit Users 2Health News:Novatus Releases v5.1 with New Advanced Reporting Capabilities 2Health News:Dr. Diane Walder Introduces New Fat Reduction Treatment Called Ultrashape 2Health News:Dr. Diane Walder Introduces New Fat Reduction Treatment Called Ultrashape 3
... called NFATc1 tends to cause massive bone accumulation that ... investigator Gerald Crabtree and HHMI predoctoral fellow Monte Winslow ... formed and being broken down throughout life. Cells called ... it. ,‘Ideally, they are perfectly balanced,’ ...
... useful for the young doctors, to overcome the fatigue, who ... a little of sleep will lead to a substantial improvement ... doctors ability to care for their patients. ,In the ... researchers from the University of Chicago report that although average ...
... under-diagnosed till now was found to be more prevalent ... Explosive Disorder or Rage disorder is characterized by recurrent ... if left untreated may also lead to other mental ... attacks are out of proportion to the social stressors ...
... has revealed that men reaching fatherhood late in life may ... the genetic damage that increases with age//. ,US ... non-smoking men aged 22 to 80 and found a prevalence ... can be manifested as symptoms such as infertility, difficulty in ...
... The House of Representatives have passed a controversial bill ... would effectively take away //the power from local & ... foods and beverages that are likely to cause cancer, ... substances like mercury, like those required in California and ...
... for people with mild asthma, shallow breathing through the ... people to use a reliever inhaler very rarely//. ... are the most commonly used alternative for inhalers. A ... used by many people with asthma. ,Since ...
Cached Medicine News:Health News:Osteoporosis – A New Treatmen 2Health News:Osteoporosis – A New Treatmen 3Health News:Small Naps are Beneficial for Doctors to Overcome Fatigue 2Health News:Small Naps are Beneficial for Doctors to Overcome Fatigue 3Health News:Intermittent Explosive Disorder is More Prevalent Now Than Before 2Health News:Intermittent Explosive Disorder is More Prevalent Now Than Before 3Health News:Fathering Best Done In Early Years 2Health News:Association Asks People To Tell Their Senator To Vote against The "National Food Uniformity Act" 2
... C-peptide of insulin is the C-terminal cleavage ... prohormone to the mature insulin molecule. Although ... it does undergo significant liver or extra-renal ... circulating half-life than insulin [1]. In addition, ...
... exists as unbound or free testosterone. The ... with high affinity [1], while the remainder ... albumin-bound and free fractions may be biologically ... Measurement of the free or unbound fraction ...
... is a 32 kDa glycoprotein secreted by ... gland [1]. The structure of human TSH ... and placental gonadotropins, consisting of an a-subunit ... hormones and a unique beta-subunit, which confers ...
... Triiodothyronine (T3) is produced primarily by 5-monodeioination ... the thyroid gland, T3 production occurs at ... that for T4. Release of T3 from ... ~5-8 micrograms/day as compared to 80-100 micrograms/day ...
Medicine Products: